Research HTC
Current Clinical Research – ºÚÁÏÍø Blood Research Center  *as of February 13, 2024*
Active Studies – Start-Up Phase
BMN 270-401– A Long-Term Follow-Up Study in Subjects With Severe Hemophilia A Who Received BMN 270, an Adeno-Associated Virus Vector-Mediated Gene Transfer of Human Factor VIII in a Prior BioMarin Clinical Trial
Please for more information.
CSL222_3003 – Long-Term Follow-Up Study of Male Adults With Hemophilia B Previously Treated With Etranacogene Dezaparvovec (CSL222)
Please for more information.
SPK-8011-302 – Phase 3 gene therapy study of SPK-8011 in adults with severe or moderately severe hemophilia A (KEYSTONESM 1)
Please for more information.
AHAEMI – Emicizumab in Patients With Acquired Hemophilia A: Multicenter, Single-Arm, Open-Label Clinical Trial
Please for more information.
Active Studies – Currently Open to Enrollment
STOP-HHT – A Phase II/III randomized, placebo controlled, double blind study to evaluate the effects of up to 24 weeks of low dose pazopanib on hereditary hemorrhagic telangiectasia related epistaxis and anemia
Please for more information.
P200 – United States Thrombotic Microangiopathy (USTMA) Thrombotic Thrombocytopenic Purpura (TTP) Clinical Data and Biologic Sample Repository
Please for more information.
BVMC3 – Brain Vascular Malformation Consortium (BVMC3) Project 3: Cerebral Hemorrhage Risk in Hereditary Hemorrhagic Telangiectasia
Please for more information.
Active Studies – Currently Following Subjects or Data Analysis Only
PATH-HHT – Placebo-controlled, double-blind study of pomalidomide in patients with hereditary hemorrhagic telangiectasia (HHT).
±Ê±ô±ð²¹²õ±ðÌý for more information.
GENEr8-1 (BMN 270-301) – Phase III, gene therapy trial for adults with severe hemophilia A.
±Ê±ô±ð²¹²õ±ðÌý for more information.
HOPE-B (CSL222) – Phase III, gene therapy trial for adults with severe or moderately severe hemophilia B.
±Ê±ô±ð²¹²õ±ðÌý for more information.
AVA-ITP-401– Phase IV trial of safety and satisfaction in adults with chronic Immune Thrombocytopenia (ITP) after switching to avatrombopag from eltrombopag or romiplostim.
±Ê±ô±ð²¹²õ±ðÌý for more information.
Recently Closed Studies (Jan 1 2023 – Present)
ACCRU-SC-1601 (EVE) – Randomized, phase III trial of apixaban in preventing secondary cancer related venous thrombosis.
±Ê±ô±ð²¹²õ±ðÌý for more information.
MOSH Outcomes – An observational study of the natural history of outcomes in hemophiliacs undergoing major orthopedic surgery.
Please for more information.